Table 1.
Baseline characteristics at diagnosis in CD patients with or without hyperlipidemia.
| Total | NLP | HLP | p | |
|---|---|---|---|---|
| Patient(n/%) | 104(100%) | 68(65.4%) | 36(34.6%) | – |
| Age(years) | 33.02 ± 11.73 | 32.41 ± 10.51 | 34.17 ± 13.81 | 0.508 |
| Gender(Female)(n/%) | 85(81.7%) | 53(77.9%) | 32(88.9%) | 0.194 |
| BMI(kg/m2) | 26.55(25.07–28.86) | 26.28(24.97–28.44) | 27.14(25.74–30.18) | 0.158 |
| Obesity(n/%) | 34(32.7%) | 19(27.9%) | 15(41.7%) | 0.156 |
| Disease duration (months) | 24.00(12.00–60.00) | 24.00(12.75–60.00) | 24.00(10.50–81.00) | 0.683 |
| SBP(mmHg) | 139.35 ± 17.69 | 136.65 ± 16.51 | 144.44 ± 18.93 | 0.032* |
| DBP(mmHg) | 92.40 ± 14.65 | 91.85 ± 13.98 | 93.44 ± 16.01 | 0.601 |
| HT(n/%) | 76(73.1%) | 48(70.6%) | 28(77.8%) | 0.432 |
| TC(mmol/L) | 5.74 ± 1.15 | 5.13 ± 0.72 | 6.91 ± 0.85 | <0.001* |
| TG(mmol/L) | 1.43(0.98–2.00) | 1.24(0.89–1.65) | 2.24(1.54–3.34) | <0.001* |
| HDL-c(mmol/L) | 1.40(1.19–1.64) | 1.40(1.19–1.62) | 1.41(1.16–1.74) | 0.534 |
| LDL-c(mmol/L) | 3.53(3.01–4.04) | 3.21(2.58–3.58) | 4.14(3.81–4.73) | <0.001* |
| Total/HDL-c Ratio | 3.97(3.28–4.98) | 3.77(3.17–4.34) | 5.01(3.85–5.61) | <0.001* |
| FBG(mmol/L) | 4.90(4.50–5.63) | 4.80(4.48–5.40) | 5.20(4.50–6.08) | 0.102 |
| 2h-BG(mmol/L) | 9.45(7.18–13.68) | 8.85(6.60–13.68) | 10.45(8.65–14.03) | 0.015* |
| HbA1c(%) | 5.50(5.20–5.90) | 5.50(5.10–5.90) | 5.70(5.30–6.30) | 0.108 |
| IGM(n/%) | 73(70.2%) | 41(60.3%) | 32(88.9%) | 0.002* |
| F[8am](μg/dl) | 27.30(20.70–32.36) | 24.98(19.97–31.36) | 29.98(22.81–36.93) | 0.041* |
| ACTH(pg/ml) | 63.60(49.45–97.55) | 59.45(43.85–95.43) | 66.85(54.23–107.75) | 0.241 |
| 24hUFC(μg) | 412.5(264.17–614.28) | 417.55(265.34–630.3) | 367.2(254.75–557.82) | 0.564 |
| Tumor size(mm) | 5.40(4.63–7.98) | 5.40(4.70–7.65) | 5.25(4.45–8.75) | 0.986 |
| Visceral obesity(n/%) | 79(76.0%) | 48(70.6%) | 31(86.1%) | 0.095 |
| Osteoporosis(n/%) | 52(50%) | 36(52.9%) | 16(44.4%) | 0.410 |
| Hepatic steatosis(n/%) | 33(31.7%) | 18(26.5%) | 15(41.7%) | 0.113 |
| Atherosclerosis(n/%) | 11(10.6%) | 7(10.3%) | 4(11.1%) | 1.000 |
| CVD history(n/%) | 13(12.5%) | 6(8.8%) | 7(19.4%) | 0.119 |
| HT family history(n/%) | 32(30.8%) | 17(25.0%) | 15(41.7%) | 0.080 |
| DM family history(n/%) | 10(9.6%) | 3(4.4%) | 7(19.4%) | 0.030* |
| Antihypertensive medication(n/%) | 58(55.8%) | 35(51.5%) | 23(63.9%) | 0.225 |
| Antidiabetic medication (n/%) | 12(11.5%) | 9(13.2%) | 3(8.3%) | 0.537 |
HLP, hyperlipidemia; NLP, non-hyperlipidemia; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HT, hypertension; TC, total cholesterol; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; FBG, fasting blood glucose; 2h-BG, 2h-blood glucose during OGTT; IGM, impaired glucose metabolism; F[8am], serum cortisol (8am); ACTH, adrenocorticotropic hormone; 24hUFC, 24-h urine free cortisol; CVD, cardiovascular disease; DM, diabetes mellitus. *Statistically significant.